Next Generation Cancer Diagnostics Market By Technology (Lab-On-A-Chip, Dna Microarrays, Multiplexed Assays, Multiplexed Assays, Rt-Pcr & Multiplexing, Protein Microarrays, Cellular Capture And Identification, Next Generation Sequencing, Benchtop Sequencers), By Cancer Type (Sex-Related Tumors, Blood-Born Cancers, Lung Cancer, Solid Tumors, Colorectal Cancer), By Function (Prognosis Diagnostics, Companion Diagnostics, Cancer Screening, Risk Analysis, Therapeutic Monitoring) By Applications (Proteomic Analysis, Epigenetic Analysis, Genetic Analysis, Biomaker Development, Ctc Analysis), Industry Size, Growth, Share And Forecast To 2022

Published By: Brisk Insights | Published On: Jun 14, 2016

Key Findings


The global next generation cancer diagnostics market was estimated to be around $2.95 billion in 2015 and is forecasted to reach around $20.93 billion at a CAGR of 32.30% during 2015-2022. The major factors that drive this global next generation cancer diagnostics market is the rising number of chronic diseases like lung cancer, solid cancer etc. along with rising geriatric population which helps in boosting the growth of the next generation cancer diagnostics market in next 6 to 7 years. Usage of cancer diagnostics devices is rising across the world due to increasing technological advancements in various fields like medical as well as the growing demand for miniaturized advanced technologies that is expected to boost this market. The rising adoption of new technologies helps in minimizing the long stay of patients in the hospitals which also helps in boosting the next generation cancer diagnostics market. Huge investment by various economies is boosting the global next generation cancer diagnostics market. Another major factor that drives this market is the increasing number of hospitals and favorable government initiatives which helps in fueling the market growth. As far as region is concerned, Asia Pacific market is expected to grow at higher rate in 2015-2022 due to rising healthcare expenditures in developing countries like India, China etc. Although there are many factors which drive the market but still there are various challenges that are faced by the next generation cancer diagnostics market such as stringent rule and regulations and rising competition among the key players which adversely affects the market. There are some major restraints which affect the growth of this market such as the rising capital investment and dearth of skilled labor. These restraints hinder the growth of the market. Rising healthcare industry across the world is another major factor which helps in boosting this market during the forecast period of time.


Market Segment Insight


The global next generation cancer diagnostics market is majorly segmented on the basis of technologies such as lab-on-a-chip, DNA microarrays, multiplexed assays, RT-PCR & multiplexing, protein microarrays, cellular capture and identification, next generation sequencing, bench top sequencers and other technologies. Among all technologies, RT-PCR & multiplexing accounted for largest market share in 2014 due to rising product range that caters to various applications in oncology R&D. Whereas, the usage of next generation sequencing solutions in cancer diagnostics is forecasted to witness significant growth in revenue over the period of time. On the basis of cancer type, the market is further segmented into sex-related tumors (cervical cancer, breast cancer, ovarian cancer, prostate cancer), blood-born cancers (myeloma, leukemia, lymphoma), lung cancer, solid tumors, colorectal cancer and other cancers. Among all cancer type, blood-born cancer held largest market share in 2015 due to rising number of cancer patients suffering from myeloma, leukemia or lymphoma etc. On the basis of function, the market is segmented into prognosis diagnostics, companion diagnostics, cancer screening, risk analysis and therapeutic monitoring. On the basis of applications, the market is further segmented into proteomic analysis, epigenetic analysis, genetic analysis, biomarker development and CTC analysis. Among all applications, epigenetic analysis and CTC analysis is generally used for monitoring tumorigenesis, which is expected to grow during the forecast period of time.


Regional Insight


Based on region this market is segmented into North America, Europe, APAC and Row. North America holds the largest market share and is the fastest growing region followed by Asia Pacific, Europe and Row. The major reason behind the growth of this market in this region is the rising number of hospitals and increasing investments for improving hospitals infrastructure. Another reason for the growth of this next generation cancer diagnostics market is the increasing investments by companies for exploring new technologies to improve diagnostics procedure etc. The Asia Pacific region is the fastest growing region for the next generation cancer diagnostics market due to rising geriatric population and growing technological advancements in healthcare sector etc. and is forecasted to grow significantly in the near future. Key players are also focusing on next generation cancer diagnostics market due to favorable government initiatives as well as investments by various economies for getting better response in future. Rising disposable income is another major factor which helps in growth of next generation cancer diagnostics market.


Competitive Insights


Some of the major market players are Abbott Laboratories, Agilent Technologies Inc, GE Healthcare, Genomic Health Inc, Hologic Inc., Illumina Inc., Johnson & Johnson, Myriad Genetics Inc., Novartis AG, Opko Health Inc., Perkin Elmer Inc. and many more. Acquisitions, expansions and mergers are the key strategies adopted by the market players to sustain in the market. On 27th March 2015, Johnson & Johnson had announced its collaboration with Google for the purpose of advance surgical robots. This collaboration benefits patients, surgeons and healthcare systems. And it continuously enlarges its way to improve is technique for the betterment of patients.

CHAP 1. METHODOLOGY & SCOPE 16
1.1. RESEARCH METHODOLOGY 16
1.2. RESEARCH SCOPE & ASSUMPTIONS 16
1.3. LIST OF DATA SOURCES 16


CHAP 2. EXECUTIVE SUMMARY 17
2.1. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET SUMMARY & KEY BUYING CRITERIA 17
2.2. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET OUTLOOK 17
2.3. MARKET SEGMENTATION ANALYSIS 17
2.4. MARKET SIZE AND GROWTH PROSPECTS 2012-2022 17
2.5. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET VALUE CHAIN ANALYSIS 17
2.6. VENDOR LANDSCAPE 17


CHAP 3. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET 18
3.1. MARKET DRIVER ANALYSIS 18
3.1.1. GROWING AGING POPULATION 18
3.1.2. INCREASING NUMBER OF PRIVATE DIAGNOSTICS CENTRES 18
3.1.3. FAVORABLE GOVERNMENT SUPPORT 18
3.1.4. INCREASING PREVALANCE RATE OF CANCER 18
3.2. MARKET RESTRAINT ANALYSIS 18
3.2.1. HIGH INVESTMENT OF CAPITAL 18
3.2.2. DEARTH OF EXPERIENCED AND SKILLED PERSONNEL 18
3.3. KEY OPPORTUNITIES 18
3.3.1. RISING TECHNOLOGICAL ADVANCEMENTS 18
3.3.2. INCREASING HEALTHCARE INDUSTRY 18
3.3.3. MINIATURIZED ADVANCED DEVICES 18
3.4. CHALLENGES 18
3.4.1. STRINGENT REGULATORY GUIDELINES 18
3.4.2. RISING COMPETITION AMONG MARKET PLAYERS 18


CHAP 4. INDUSTRY ANALYSIS 19
4.1. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET– PORTER’S FIVE FORCE MODEL 19
4.2. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET– PESTEL ANALYSIS 19
4.3. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET– GAP ANALYSIS 19


CHAP 5. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY TECHNOLOGY 2012-2022 ($ BILLION) 20
5.1. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY LAB-ON-A-CHIP 2012-2022 ($ BILLION) 20
5.2. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY DNA MICROARRAYS 2012-2022 ($ BILLION) 20
5.3. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY MULTIPLEXED ASSAYS 2012-2022 ($ BILLION) 20
5.4. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY MULTIPLEXED ASSAYS 2012-2022 ($ BILLION) 20
5.5. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY RT-PCR & MULTIPLEXING 2012-2022 ($ BILLION) 20
5.6. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY PROTEIN MICROARRAYS 2012-2022 ($ BILLION) 20
5.7. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY CELLULAR CAPTURE AND IDENTIFICATION 2012-2022 ($ BILLION) 20
5.8. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY NEXT GENERATION SEQUENCING 2012-2022 ($ BILLION) 20
5.9. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY BENCHTOP SEQUENCERS 2012-2022 ($ BILLION) 20
5.10. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY OTHERS TECHNOLOGIES 2012-2022 ($ BILLION) 20


CHAP 6. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY CANCER TYPE 2012-2022 ($ BILLION) 21
6.1. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY SEX-RELATED TUMORS 2012-2022 ($ BILLION) 21
6.1.1. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY CERVICAL CANCER 2012-2022 ($ BILLION) 21
6.1.2. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY BREAST CANCER 2012-2022 ($ BILLION) 21
6.1.3. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY OVARIAN CANCER 2012-2022 ($ BILLION) 21
6.1.4. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY PROSTATE CANCER 2012-2022 ($ BILLION) 21
6.2. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY BLOOD-BORN CANCERS 2012-2022 ($ BILLION) 21
6.2.1. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY MYELOMA 2012-2022 ($ BILLION) 21
6.2.2. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY LEUKAMIA 2012-2022 ($ BILLION) 21
6.2.3. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY LYMPHOMA 2012-2022 ($ BILLION) 21
6.3. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY LUNG CANCER 2012-2022 ($ BILLION) 21
6.4. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY SOLID TUMORS 2012-2022 ($ BILLION) 21
6.5. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY COLORECTAL CANCER 2012-2022 ($ BILLION) 21
6.6. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY OTHER CANCER 2012-2022 ($ BILLION) 21


CHAP 7. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY FUNCTION 2012-2022 ($ BILLION) 22
7.1. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY PROGNOSIS DIAGNOSTICS 2012-2022 ($ BILLION) 22
7.2. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY COMPANION DIAGNOSTICS 2012-2022 ($ BILLION) 22
7.3. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY CANCER SCREENING 2012-2022 ($ BILLION) 22
7.4. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY RISK ANALYSIS 2012-2022 ($ BILLION) 22
7.5. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY THERAPEUTIC MONITORING 2012-2022 ($ BILLION) 22


CHAP 8. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY APPLICATIONS 2012-2022 ($ BILLION) 23
8.1. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY PROTEOMIC ANALYSIS 2012-2022 ($ BILLION) 23
8.2. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY EPIGENETIC ANALYSIS 2012-2022 ($ BILLION) 23
8.3. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY GENETIC ANALYSIS 2012-2022 ($ BILLION) 23
8.4. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY BIOMAKER DEVELOPMENT 2012-2022 ($ BILLION) 23
8.5. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY CTC ANALYSIS 2012-2022 ($ BILLION) 23


CHAP 9. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET REGIONAL OUTLOOK 2012-2022 ($ BILLION) 24
9.1. GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY REGION 2012-2022 ($ BILLION) 24
9.2. NORTH AMERICA 24
9.2.1. NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 24
9.2.2. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 24
9.2.3. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 24
9.2.3.1. U.S. 24
9.2.3.1.1. U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 24
9.2.3.1.2. U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 24
9.2.3.2. CANADA 24
9.2.3.2.1. CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 24
9.2.3.2.2. CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 24
9.2.3.3. MEXICO 24
9.2.3.3.1. MEXICO MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 24
9.2.3.3.2. MEXICO MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 24
9.3. EUROPE 25
9.3.1. EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 25
9.3.2. EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 25
9.3.3. EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 25
9.3.3.1. GERMANY 25
9.3.3.1.1. GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 25
9.3.3.1.2. GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 25
9.3.3.2. UK 25
9.3.3.2.1. UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 25
9.3.3.2.2. UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 25
9.3.3.3. FRANCE 25
9.3.3.3.1. FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 25
9.3.3.3.2. FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 25
9.3.3.4. ITALY 25
9.3.3.4.1. ITALY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 25
9.3.3.4.2. ITALY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 25
9.3.3.5. SPAIN 25
9.3.3.5.1. SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 26
9.3.3.5.2. SPAIN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 26
9.3.3.6. REST OF EUROPE 26
9.3.3.6.1. OTHERS MARKET ESTIMATES AND FORECAST2012-2022($ BILLION) 26
9.3.3.6.2. OTHERS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($ BILLION) 26
9.4. ASIA PACIFIC 26
9.4.1. ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 26
9.4.2. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 26
9.4.3. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 26
9.4.3.1. CHINA 26
9.4.3.1.1. CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 26
9.4.3.1.2. CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 26
9.4.3.2. INDIA 26
9.4.3.2.1. INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 26
9.4.3.2.2. INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 26
9.4.3.3. JAPAN 26
9.4.3.3.1. JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 27
9.4.3.3.2. JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 27
9.4.3.4. AUSTRALIA 27
9.4.3.4.1. AUSTRALIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 27
9.4.3.4.2. AUSTRALIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 27
9.4.3.5. NEW ZEALAND 27
9.4.3.5.1. NEW ZEALAND MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 27
9.4.3.5.2. NEW ZEALAND MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 27
9.4.3.6. OTHERS 27
9.4.3.6.1. OTHER MARKET ESTIMATES AND FORECASTS 2012-2022($ BILLION) 27
9.4.3.6.2. OTHER MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($ BILLION) 27
9.5. REST OF THE WORLD 27
9.5.1. MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 27
9.5.2. MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 27
9.5.3. LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 27
9.5.4. LATIN AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 27


CHAP 10. COMPETITIVE LANDSCAPE 28
10.1. ABBOTT LABORATORIES 29
10.1.1. COMPANY OVERVIEW 29
10.1.2. SCOT ANALYSIS 29
10.1.3. PRODUCT BENCHMARKING 29
10.1.4. STRATEGIC INITIATIVES 29
10.2. AGILENT TECHNOLOGIES INC 29
10.2.1. COMPANY OVERVIEW 29
10.2.2. SCOT ANALYSIS 29
10.2.3. PRODUCT BENCHMARKING 29
10.2.4. STRATEGIC INITIATIVES 29
10.3. GE HEALTHCARE 29
10.3.1. COMPANY OVERVIEW 29
10.3.2. SCOT ANALYSIS 29
10.3.3. PRODUCT BENCHMARKING 29
10.3.4. STRATEGIC INITIATIVES 29
10.4. GENOMIC HEALTH INC. 29
10.4.1. COMPANY OVERVIEW 29
10.4.2. SCOT ANALYSIS 29
10.4.3. PRODUCT BENCHMARKING 29
10.4.4. STRATEGIC INITIATIVES 29
10.5. HOLOGIC INC. 29
10.5.1. COMPANY OVERVIEW 29
10.5.2. SCOT ANALYSIS 29
10.5.3. PRODUCT BENCHMARKING 29
10.5.4. STRATEGIC INITIATIVES 29
10.6. ILLUMINA INC. 29
10.6.1. COMPANY OVERVIEW 29
10.6.2. SCOT ANALYSIS 30
10.6.3. PRODUCT BENCHMARKING 30
10.6.4. STRATEGIC INITIATIVES 30
10.7. JOHNSON & JOHNSON 30
10.7.1. COMPANY OVERVIEW 30
10.7.2. SCOT ANALYSIS 30
10.7.3. PRODUCT BENCHMARKING 30
10.7.4. STRATEGIC INITIATIVES 30
10.8. MYRIAD GENETICS INC. 30
10.8.1. COMPANY OVERVIEW 30
10.8.2. SCOT ANALYSIS 30
10.8.3. PRODUCT BENCHMARKING 30
10.8.4. STRATEGIC INITIATIVES 30
10.9. NOVARTIS AG 30
10.9.1. COMPANY OVERVIEW 30
10.9.2. SCOT ANALYSIS 30
10.9.3. PRODUCT BENCHMARKING 30
10.9.4. STRATEGIC INITIATIVES 30
10.10. OPKO HEALTH INC. 30
10.10.1. COMPANY OVERVIEW 30
10.10.2. SCOT ANALYSIS 30
10.10.3. PRODUCT BENCHMARKING 30
10.10.4. STRATEGIC INITIATIVES 30
10.11. PERKIN ELMER INC. 30
10.11.1. COMPANY OVERVIEW 30
10.11.2. SCOT ANALYSIS 30
10.11.3. PRODUCT BENCHMARKING 30
10.11.4. STRATEGIC INITIATIVES 30
10.12. PHILIPS ELECTRONICS NV 31
10.12.1. COMPANY OVERVIEW 31
10.12.2. SCOT ANALYSIS 31
10.12.3. PRODUCT BENCHMARKING 31
10.12.4. STRATEGIC INITIATIVES 31
10.13. QIAGEN 31
10.13.1. COMPANY OVERVIEW 31
10.13.2. SCOT ANALYSIS 31
10.13.3. PRODUCT BENCHMARKING 31
10.13.4. STRATEGIC INITIATIVES 31
10.14. ROCHE HOLDING AG 31
10.14.1. COMPANY OVERVIEW 31
10.14.2. SCOT ANALYSIS 31
10.14.3. PRODUCT BENCHMARKING 31
10.14.4. STRATEGIC INITIATIVE 31
10.15. THERMO FISHER SCIENTIFIC INC. 31
10.15.1. COMPANY OVERVIEW 31
10.15.2. SCOT ANALYSIS 31
10.15.3. PRODUCT BENCHMARKING 31
10.15.4. STRATEGIC INITIATIVES 31

TABLE 1 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY TECHNOLOGY 2012-2022 ($ BILLION) 31
TABLE 2 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY LAB-ON-A-CHIP 2012-2022 ($ BILLION) 31
TABLE 3 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY DNA MICROARRAYS 2012-2022 ($ BILLION) 31
TABLE 4 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY MULTIPLEXED ASSAYS 2012-2022 ($ BILLION) 32
TABLE 5 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY MULTIPLEXED ASSAYS 2012-2022 ($ BILLION) 32
TABLE 6 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY RT-PCR & MULTIPLEXING 2012-2022 ($ BILLION) 32
TABLE 7 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY PROTEIN MICROARRAYS 2012-2022 ($ BILLION) 32
TABLE 8 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY CELLULAR CAPTURE AND IDENTIFICATION 2012-2022 ($ BILLION) 32
TABLE 9 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY NEXT GENERATION SEQUENCING 2012-2022 ($ BILLION) 32
TABLE 10 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY BENCHTOP SEQUENCERS 2012-2022 ($ BILLION) 32
TABLE 11 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY OTHERS TECHNOLOGIES 2012-2022 ($ BILLION) 32
TABLE 12 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY CANCER TYPE 2012-2022 ($ BILLION) 32
TABLE 13 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY SEX-RELATED TUMORS 2012-2022 ($ BILLION) 32
TABLE 14 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY CERVICAL CANCER 2012-2022 ($ BILLION) 32
TABLE 15 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY BREAST CANCER 2012-2022 ($ BILLION) 32
TABLE 16 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY OVARIAN CANCER 2012-2022 ($ BILLION) 32
TABLE 17 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY PROSTATE CANCER 2012-2022 ($ BILLION) 32
TABLE 18 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY BLOOD-BORN CANCERS 2012-2022 ($ BILLION) 32
TABLE 19 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY MYELOMA 2012-2022 ($ BILLION) 32
TABLE 20 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY LEUKAMIA 2012-2022 ($ BILLION) 32
TABLE 21 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY LYMPHOMA 2012-2022 ($ BILLION) 33
TABLE 22 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY LUNG CANCER 2012-2022 ($ BILLION) 33
TABLE 23 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY SOLID TUMORS 2012-2022 ($ BILLION) 33
TABLE 24 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY COLORECTAL CANCER 2012-2022 ($ BILLION) 33
TABLE 25 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY OTHER CANCER 2012-2022 ($ BILLION) 33
TABLE 26 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY FUNCTION 2012-2022 ($ BILLION) 33
TABLE 27 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY PROGNOSIS DIAGNOSTICS 2012-2022 ($ BILLION) 33
TABLE 28 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY COMPANION DIAGNOSTICS 2012-2022 ($ BILLION) 33
TABLE 29 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY CANCER SCREENING 2012-2022 ($ BILLION) 33
TABLE 30 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY RISK ANALYSIS 2012-2022 ($ BILLION) 33
TABLE 31 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY THERAPEUTIC MONITORING 2012-2022 ($ BILLION) 33
TABLE 32 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY APPLICATIONS 2012-2022 ($ BILLION) 33
TABLE 33 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY PROTEOMIC ANALYSIS 2012-2022 ($ BILLION) 33
TABLE 34 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY EPIGENETIC ANALYSIS 2012-2022 ($ BILLION) 33
TABLE 35 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY GENETIC ANALYSIS 2012-2022 ($ BILLION) 33
TABLE 36 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY BIOMAKER DEVELOPMENT 2012-2022 ($ BILLION) 33
TABLE 37 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY CTC ANALYSIS 2012-2022 ($ BILLION) 33
TABLE 38 GLOBAL NEXT GENERATION CANCER DIAGNOSTICS MARKET BY REGION 2012-2022 ($ BILLION) 34
TABLE 39 NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34
TABLE 40 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 34
TABLE 41 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 34
TABLE 42 U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34
TABLE 43 U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 34
TABLE 44 CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34
TABLE 45 CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 34
TABLE 46 MEXICO MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34
TABLE 47 MEXICO MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 34
TABLE 48 EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34
TABLE 49 EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 34
TABLE 50 EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 34
TABLE 51 GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34
TABLE 52 GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 34
TABLE 53 UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34
TABLE 54 UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 34
TABLE 55 FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 35
TABLE 56 FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 35
TABLE 57 ITALY MARKET ESTIMATES AND FORECAST2012-2022($ BILLION) 35
TABLE 58 ITALY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 35
TABLE 59 SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 35
TABLE 60 SPAIN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 35
TABLE 61 OTHERS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($ BILLION) 35
TABLE 62 ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 35
TABLE 63 ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 35
TABLE 64 ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 35
TABLE 65 CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 35
TABLE 66 CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 35
TABLE 67 INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 35
TABLE 68 INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 35
TABLE 69 JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 35
TABLE 70 JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 35
TABLE 71 AUSTRALIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 35
TABLE 72 AUSTRALIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 36
TABLE 73 NEW ZEALAND MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 36
TABLE 74 NEW ZEALAND MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 36
TABLE 75 OTHER MARKET ESTIMATES AND FORECASTS 2012-2022($ BILLION) 36
TABLE 76 OTHER MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($ BILLION) 36
TABLE 77 REST OF THE WORLD MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 36
TABLE 78 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 36
TABLE 79 LATIN AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 36

FIGURE 1 MARKET SHARE BY REGIONS 36
FIGURE 2 UNITED STATES MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 36
FIGURE 3 CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 36
FIGURE 4 MEXICO MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 36
FIGURE 5 EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 36
FIGURE 6 GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 36
FIGURE 7 UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 36
FIGURE 8 FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 37
FIGURE 9 ITALY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 37
FIGURE 10 SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 37
FIGURE 11 APAC MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 37
FIGURE 12 CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 37
FIGURE 13 INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 37
FIGURE 14 JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 37
FIGURE 15 AUSTRALIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 37
FIGURE 16 NEW ZEALAND MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 37
FIGURE 17 REST OF THE WORLD MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 37
FIGURE 18 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 37
FIGURE 19 LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 37

Choose License


Contact Information

: 24/7 Research Support

: sales@briskinsights.com

: +448081890034 (UK)